Por: ABC News Health January 27, 2023
The U.S. Food and Drug Administration said Thursday it is withdrawing its emergency use authorization of a as a prevention tool because it is unlikely to be effective against variants that are currently circulating.Evusheld, which is made by British-Swedish pharmaceutical and biotechnology company, AstraZeneca, was first authorized in December 2021 as pre-exposure prophylaxis against the virus for those who are immunocompromised and less likely... + full article
ABC7 USA Health January 27, 2023
The US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against COVID-19 from viral variants currently circulating in the United States.The video in the media player is from a previous... + más
FDA withdraws emergency use authorization of COVID drug because it is unlikely to be effective against new variants | ABC News
FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants | CNBC
Politico USA Health December 30, 2022
The FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House... + más
Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Fox Business USA Business December 02, 2022
Fox News medical contributor Dr. Marty Makary discusses the 'unique set' of long COVID symptoms and explains why it's not likely to become the next public health disaster on 'Varney & Co.' The Food and Drug Administration announced on Wednesday that is... + más
Twitter was once a necessity for major brands. Under Elon Musk, it's now high risk. | CBS News
FDA pauses authorization for last remaining COVID-19 monoclonal antibody treatment | The Hill
NBC 6 South Florida USA World October 26, 2022
monkeybusinessimages Getty Images Though BA.5 still accounts for most U.S. Covid-19 cases, percentages are rising for the other omicron variants circulating throughout the country, per the . The ones that are particularly concerning are BQ.1 and another related one called... + más
Quick and stealthy 'Scrabble variants' are poised to drive a winter Covid-19 surge | CNN
Biden Covid officials scramble to plan for Omicron subvariant threat | Politico
CNN USA Health October 20, 2022
CNN — A flurry of new Covid-19 variants appears to be gaining traction globally, raising fears of a winter surge. In the United States, these are BQ.1, BQ.1.1, BF.7, BA.4.6, BA.2.75 and BA.2.75.2. In other countries, the recombinant variant XBB has been rising quickly and... + más
What is storm surge, and what contributes to the deadly hurricane hazard? | CBS News
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | WPLG Local 10
About iurex | Privacy Policy | Disclaimer |